RxDoctor Payments Data

Daniel Callaghan, MD

Family Medicine · Rocky Hill, CTNPI 1124032941

Payments from drug & device makers

$523in general payments, 2019–2025

Across 21 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$159
  • Baxter Healthcare$78
  • AbbVie$54
  • GSK$49
  • Lilly USA, LLC$45
  • Novo Nordisk$33
  • plus $105 from 6 others

What the payments were for

  • Food & beverage$43483%
  • Education$122%
  • Other$7815%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$523 in reported general payments places this provider in the 60th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$73,076
Medicare patients
173
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$107,983
OzempicSemaglutide58$70,958
JanuviaSitagliptin Phosphate47$61,064
FarxigaDapagliflozin Propanediol28$37,056
XareltoRivaroxaban34$34,727
JardianceEmpagliflozin19$30,206
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$25,711
Lantus SolostarInsulin Glargine,hum.Rec.Anlog84$15,560
EntrestoSacubitril/Valsartan20$13,158
MounjaroTirzepatide11$11,660
Humalog Kwikpen U-100Insulin Lispro41$10,427
Spiriva RespimatTiotropium Bromide11$8,573
Spiriva HandihalerTiotropium Bromide11$7,719
Dexlansoprazole DrDexlansoprazole16$5,347
Atorvastatin Calcium523$4,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$107,983116 claims
Novo NordiskOzempic$33$70,95858 claims
AstraZenecaFarxiga$159$37,05628 claims
GSKTrelegy Ellipta$49$25,71133 claims
NovartisEntresto$21$13,15820 claims
Lilly USA, LLCMounjaro$45$11,66011 claims
AbbVieSynthroid$54$4,50649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Rocky Hill

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →